We are live on
!
Find out more
TCM
TCG Crossover Management Portfolio holdings
AUM
$3.5B
1-Year Est. Return
1,165.83%
This Fund
S&P 500
This Quarter
Est. Return
+38.46%
1 Year Est. Return
+1,165.83%
3 Year Est. Return
+3,168.76%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.26B
AUM Growth
+$363M
(+40%)
Cap. Flow
+$234M
Cap. Flow
% of AUM
18.46%
Top 10 Holdings %
Top 10 Hldgs %
58.32%
Holding
38
New
9
Increased
5
Reduced
7
Closed
5
Top Buys
| 1 |
CG Oncology
CGON
|
+$146M |
| 2 |
ATXS
Astria Therapeutics
ATXS
|
+$65.7M |
| 3 |
Keros Therapeutics
KROS
|
+$52.1M |
| 4 |
Mineralys Therapeutics
MLYS
|
+$39.3M |
| 5 |
Ocular Therapeutix
OCUL
|
+$37.7M |
Top Sells
| 1 |
ICVX
Icosavax, Inc. Common Stock
ICVX
|
+$58.4M |
| 2 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
+$54.1M |
| 3 |
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
|
+$45.3M |
| 4 |
KALV
KalVista Pharmaceuticals
KALV
|
+$29.8M |
| 5 |
Structure Therapeutics
GPCR
|
+$21.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
CG Oncology
CGON
$6.11B
| $157M | 12.39% |
+3,570,206
| New | +$146M |
|
2
Dyne Therapeutics
DYN
$3.75B
| $75.2M | 5.95% |
2,650,150
+1,000,000
| +61% | +$22.6M |
|
|
ATXS
3
DELISTED
Astria Therapeutics
ATXS
| $74.3M | 5.87% |
+5,278,928
| New | +$65.7M |
|
|
SLN
4
Silence Therapeutics
SLN
$491M
| $71.2M | 5.63% |
3,295,350
+1,190,475
| +57% | +$25.9M |
|
|
5
Structure Therapeutics
GPCR
$3.3B
| $68.5M | 5.42% |
1,598,421
-511,163
| -24% | -$21.6M |
|
|
JBIO
6
Jade Biosciences
JBIO
$1.24B
| $65.1M | 5.15% |
62,894
| – | – |
|
|
INBX
7
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $61.2M | 4.84% |
1,750,387
| – | – |
|
|
8
Keros Therapeutics
KROS
$209M
| $58.2M | 4.6% |
+879,344
| New | +$52.1M |
|
9
Geron
GERN
$911M
| $57.4M | 4.54% |
17,391,639
-5,984,200
| -26% | -$13.4M |
|
10
Savara
SVRA
$1.15B
| $49.8M | 3.94% |
10,000,000
| – | – |
|
|
11
Ocular Therapeutix
OCUL
$1.99B
| $48.4M | 3.83% |
+5,319,148
| New | +$37.7M |
|
12
Cogent Biosciences
COGT
$6.54B
| $41.8M | 3.3% |
6,214,375
+583,333
| +10% | +$3.61M |
|
13
Edgewise Therapeutics
EWTX
$4.21B
| $41.5M | 3.28% |
+2,272,728
| New | +$36.1M |
|
|
14
Mineralys Therapeutics
MLYS
$2.37B
| $41.1M | 3.25% |
+3,185,185
| New | +$39.3M |
|
15
Madrigal Pharmaceuticals
MDGL
$12.4B
| $39.9M | 3.15% |
149,283
-30,634
| -17% | -$7.22M |
|
|
TRML
16
DELISTED
Tourmaline Bio
TRML
| $33.8M | 2.68% |
1,477,593
+469,691
| +47% | +$16.6M |
|
17
Tyra Biosciences
TYRA
$1.88B
| $32.6M | 2.58% |
1,989,103
| – | – |
|
|
CMPS
18
Compass Pathways
CMPS
$1.72B
| $32.1M | 2.54% |
3,858,000
| – | – |
|
19
Kura Oncology
KURA
$963M
| $30.4M | 2.4% |
1,423,642
| – | – |
|
20
Tarsus Pharmaceuticals
TARS
$2.55B
| $28.9M | 2.28% |
793,829
-349,028
| -31% | -$10.3M |
|
|
ADVM
21
DELISTED
Adverum Biotechnologies
ADVM
| $28.4M | 2.25% |
+2,008,340
| New | +$30.5M |
|
|
SLNO
22
DELISTED
Soleno Therapeutics
SLNO
| $23.5M | 1.86% |
+550,000
| New | +$24.9M |
|
|
CNTA
23
DELISTED
Centessa Pharmaceuticals
CNTA
| $23.1M | 1.82% |
2,040,816
| – | – |
|
|
ABVX
24
Abivax
ABVX
$11.7B
| $15.7M | 1.24% |
1,100,000
| – | – |
|
25
VistaGen Therapeutics
VTGN
$9.69M
| $14.1M | 1.12% |
2,676,580
| – | – |
|
Similar funds
DILIC
IIM
KCM
ACM
BCP
AL
ACA
MSC